Qiagen has partnered with Sophia Genetics (NASDAQ: SOPH) to co-develop next-generation sequencing kits, according to Reuters. Financial terms were not disclosed.
The collaboration links Qiagen's reagent capabilities with Sophia Genetics' SOPHiA DDM platform, which applies AI-driven analytics to genomic data interpretation. For Qiagen, the deal adds an informatics layer to its sample-to-insight portfolio without building or acquiring a platform outright. For Sophia Genetics, a Boston-based informatics company, the partnership extends its cloud-based analytics platform into library prep, a segment where it has not historically competed.
Earlier this week, Sophia Genetics secured a CE-IVD mark for a cancer detection solution. The company has built its commercial model around analytics software deployed in clinical laboratories and hospitals.
The partnership comes as competitors pursue tighter integration. Illumina recently announced deals with Labcorp and Veritas Genetics to co-commercialize tests and launch a preventive genomics consortium. Thermo Fisher's Ion Torrent platform similarly bundles reagents, instruments, and software. MGI Tech this week said it would divest its U.S. subsidiary, citing geopolitical tensions.
Neither Qiagen nor Sophia Genetics disclosed launch timelines, target panels, or whether the partnership is exclusive.